Developing strategies for detection of gene doping

It is feared that the use of gene transfer technology to enhance athletic performance, the practice that has received the term ‘gene doping’, may soon become a real threat to the world of sport. As recognised by the anti‐doping community, gene doping, like doping in any form, undermines principles of fair play in sport and most importantly, involves major health risks to athletes who partake in gene doping. One attraction of gene doping for such athletes and their entourage lies in the apparent difficulty of detecting its use. Since the realisation of the threat of gene doping to sport in 2001, the anti‐doping community and scientists from different disciplines concerned with potential misuse of gene therapy technologies for performance enhancement have focused extensive efforts on developing robust methods for gene doping detection which could be used by the World Anti‐Doping Agency to monitor athletes and would meet the requirements of a legally defensible test. Here we review the approaches and technologies which are being evaluated for the detection of gene doping, as well as for monitoring the efficacy of legitimate gene therapy, in relation to the detection target, the type of sample required for analysis and detection methods. We examine the accumulated knowledge on responses of the body, at both cellular and systemic levels, to gene transfer and evaluate strategies for gene doping detection based on current knowledge of gene technology, immunology, transcriptomics, proteomics, biochemistry and physiology. Copyright © 2008 John Wiley & Sons, Ltd.

[1]  S. Xiong,et al.  Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice. , 2005, Immunology letters.

[2]  D. Escande,et al.  Inducible production of erythropoietin using intramuscular injection of block copolymer/DNA formulation , 2005, The journal of gene medicine.

[3]  N. Bessis,et al.  Immune responses to gene therapy vectors: influence on vector function and effector mechanisms , 2004, Gene therapy.

[4]  M. Rantalainen,et al.  Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice. , 2006, Journal of proteome research.

[5]  J. Bergh,et al.  Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors , 2000, Cancer Gene Therapy.

[6]  D. Knipe,et al.  Herpes Simplex Virus Vectors Elicit Durable Immune Responses in the Presence of Preexisting Host Immunity , 2002, Journal of Virology.

[7]  R. Morgan,et al.  Toxicity of a first-generation adenoviral vector in rhesus macaques. , 2002, Human gene therapy.

[8]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[9]  T. Flotte,et al.  Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model , 1999, Journal of Virology.

[10]  A. Fischer,et al.  Gene therapy for severe combined immunodeficiency. , 2005, Annual review of medicine.

[11]  S. Gambhir,et al.  Gene Therapy Progress and Prospects: Noninvasive imaging of gene therapy in living subjects , 2004, Gene Therapy.

[12]  Y. Oh,et al.  Prolonged organ retention and safety of plasmid DNA administered in polyethylenimine complexes , 2001, Gene Therapy.

[13]  P. Bouloux,et al.  Intramuscular plasmid DNA injection can accelerate autoimmune responses , 2001, Gene Therapy.

[14]  G. Ciliberto,et al.  Immune responses against tetracycline‐dependent transactivators affect long‐term expression of mouse erythropoietin delivered by a helper‐dependent adenoviral vector , 2005, The journal of gene medicine.

[15]  Christof M Niemeyer,et al.  Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification. , 2005, Trends in biotechnology.

[16]  Luca Malcovati,et al.  Hematologic passport for athletes competing in endurance sports: a feasibility study. , 2003, Haematologica.

[17]  J. Kaplan,et al.  Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. , 1997, Gene.

[18]  E. Marcotte,et al.  Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation , 2007, Nature Biotechnology.

[19]  V. Kosma,et al.  Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  A. Heguy,et al.  High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  C. Densmore,et al.  Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  T. Gonda,et al.  Expression of activated mutants of the human interleukin-3/interleukin-5/granulocyte-macrophage colony-stimulating factor receptor common beta subunit in primary hematopoietic cells induces factor-independent proliferation and differentiation. , 1997, Blood.

[23]  G. Rechavi,et al.  Detection of adeno-associated virus type 2 in human peripheral blood cells. , 1992, The Journal of general virology.

[24]  G. Pierce,et al.  Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. , 2000, Human gene therapy.

[25]  A. Lee,et al.  Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  O. Rekvig,et al.  Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms? , 2003, Arthritis and rheumatism.

[27]  Andy Miah,et al.  Rethinking Enhancement in Sport , 2006, Annals of the New York Academy of Sciences.

[28]  J. Markovits,et al.  Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. , 2003, Human gene therapy.

[29]  S. Gatzek,et al.  Controlled protein precipitation in combination with chip-based nanospray infusion mass spectrometry. An approach for metabolomics profiling of plasma. , 2005, Analytical chemistry.

[30]  Thibaut Larcher,et al.  "Genetic Doping" with erythropoietin cDNA in primate muscle is detectable. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  M. Atkinson,et al.  Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity , 2004, Gene Therapy.

[32]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[33]  L. Naldini,et al.  Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. , 2005, Human gene therapy.

[34]  R. Martuza,et al.  Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  O. Wildner,et al.  Subcutaneous Administration of a Replication-Competent Adenovirus Expressing HSV-tk to Cotton Rats: Dissemination, Persistence, Shedding, and Pathogenicity. , 2002, Human gene therapy.

[36]  Ying Zhang,et al.  HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..

[37]  R. Scheule,et al.  Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  J. Schlehofer,et al.  Update on the prevalence of serum antibodies (IgG and IgM) to adeno‐associated virus (AAV) , 1999, Journal of medical virology.

[39]  J. Zabner,et al.  Canine Adenovirus Vectors for Lung-Directed Gene Transfer: Efficacy, Immune Response, and Duration of Transgene Expression Using Helper-Dependent Vectors , 2006, Journal of Virology.

[40]  B. Harder,et al.  Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin. , 2001, Blood.

[41]  D. Kondziolka,et al.  Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates , 2004, Gene Therapy.

[42]  P. Cozzone,et al.  Metabolic determinants of the onset of acidosis in exercising human muscle: a 31P-MRS study. , 2003, Journal of applied physiology.

[43]  R. Ralston,et al.  Combination Nonviral Interleukin‐2 Gene Immunotherapy For Head and Neck Cancer: From Bench Top to Bedside , 2005, The Laryngoscope.

[44]  Gareth Elvidge,et al.  Microarray expression technology: from start to finish. , 2006, Pharmacogenomics.

[45]  Anna Moore,et al.  In vivo imaging of siRNA delivery and silencing in tumors , 2007, Nature Medicine.

[46]  T. Friedmann,et al.  Gene transfer and athletics- an impending problem. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  Z. Li,et al.  Sequential injection of cationic liposome and plasmid DNA effectively transfects the lung with minimal inflammatory toxicity. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  H. Roehl,et al.  Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. , 2003, Blood.

[49]  J. Rasko,et al.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.

[50]  J. Perrard,et al.  Biodistribution and safety studies of hDel‐1 plasmid‐based gene therapy in mouse and rabbit models , 2004, The Journal of pharmacy and pharmacology.

[51]  A. Gaggar,et al.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. , 2005, Human gene therapy.

[52]  L. Corey,et al.  Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research , 2003, Clinical Microbiology Reviews.

[53]  Y. Oh,et al.  Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. , 2001, Vaccine.

[54]  M. Tarnopolsky,et al.  The FASEB Journal express article 10.1096/fj.04-3149fje. Published online June 28, 2005. Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise , 2022 .

[55]  M. Hayden,et al.  Gene therapy for lipoprotein lipase deficiency: working toward clinical application. , 2005, Human gene therapy.

[56]  K. Stieger,et al.  Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[57]  R. Weissleder,et al.  Quantitation of HSV mass distribution in a rodent brain tumor model , 2000, Gene Therapy.

[58]  Theodore Friedmann,et al.  Gene doping in sports: the science and ethics of genetically modified athletes. , 2011, Advances in genetics.

[59]  L. Rozamus,et al.  Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. , 2005, Blood.

[60]  C. Dekker,et al.  A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy , 1995, Annals of Internal Medicine.

[61]  R. Samulski,et al.  Autoimmune anemia in macaques following erythropoietin gene therapy. , 2004, Blood.

[62]  Fernand Labrie,et al.  Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid. , 2005, The Journal of endocrinology.

[63]  James M. Wilson,et al.  Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. , 1998, Human gene therapy.

[64]  J. Erälinna,et al.  CYTOKINES IN EXPERIMENTAL HERPES SIMPLEX VIRUS INFECTION , 2002, International reviews of immunology.

[65]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[66]  Daniel J. Park,et al.  A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies , 2006, Nature Biotechnology.

[67]  Daniel B. Martin,et al.  Computational prediction of proteotypic peptides for quantitative proteomics , 2007, Nature Biotechnology.

[68]  H. Wakimoto,et al.  Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells , 2003, Gene Therapy.

[69]  V. Hukkanen,et al.  Immune response to herpes simplex virus and gamma134.5 deleted HSV vectors. , 2005, Current gene therapy.

[70]  J. Grandis,et al.  Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy , 2003, Cancer Gene Therapy.

[71]  Mani Menon,et al.  Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. , 2002, Cancer research.

[72]  D. Murphy Gene expression studies using microarrays: principles, problems, and prospects. , 2002, Advances in physiology education.

[73]  Iván Peñuelas,et al.  Positron emission tomography and gene therapy: basic concepts and experimental approaches for in vivo gene expression imaging. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[74]  C. Slaughter,et al.  Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. , 2002, Blood.

[75]  R. Herzog,et al.  Posttranslational modifications of recombinant myotube-synthesized human factor IX. , 2001, Blood.

[76]  S J White,et al.  Promoters and control elements: designing expression cassettes for gene therapy. , 2004, Current gene therapy.

[77]  R. Weissleder,et al.  Mapping the in vivo distribution of herpes simplex virions. , 1998, Human gene therapy.

[78]  L. Barrett,et al.  Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery , 1999, Gene Therapy.

[79]  Antonio Musarò,et al.  Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle , 2001, Nature Genetics.

[80]  Mai M H Mansour,et al.  Doping in the recombinant era: strategies and counterstrategies. , 2005, Clinical biochemistry.

[81]  D. Bohl,et al.  Lack of an Immune Response against the Tetracycline-Dependent Transactivator Correlates with Long-Term Doxycycline-Regulated Transgene Expression in Nonhuman Primates after Intramuscular Injection of Recombinant Adeno-Associated Virus , 2002, Journal of Virology.

[82]  T. Gonda,et al.  Expression of Activated Mutants of the Human Interleukin-3/Interleukin-5/Granulocyte-Macrophage Colony-Stimulating Factor Receptor Common β Subunit in Primary Hematopoietic Cells Induces Factor-Independent Proliferation and Differentiation , 1997 .

[83]  P. Opolon,et al.  Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients , 2003, Gene Therapy.

[84]  Steven G Potkin,et al.  A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease , 2005, Nature Medicine.

[85]  James M. Wilson,et al.  Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naïve and pre-immunized mice , 2005, Gene Therapy.

[86]  A. Smilde,et al.  Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. , 2006, Analytical chemistry.

[87]  Retracing events , 2007, Nature Biotechnology.

[88]  R. Martuza,et al.  Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. , 2001, Human gene therapy.

[89]  G. Cazorla,et al.  Biochemical Aspects of Overtraining in Endurance Sports , 2003, Sports medicine.

[90]  M. R. Delgado Alvira,et al.  Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues , 2004, Journal of Virology.

[91]  Kay Nieselt,et al.  cDNA microarray analysis reveals novel candidate genes expressed in human peripheral blood following exhaustive exercise. , 2005, Physiological genomics.

[92]  Lili Wang,et al.  Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[93]  Martin R Larsen,et al.  Analysis of posttranslational modifications of proteins by tandem mass spectrometry. , 2006, BioTechniques.

[94]  C. Baum What are the consequences of the fourth case? , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[95]  F. Liu,et al.  Mechanistic studies of sequential injection of cationic liposome and plasmid DNA. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[96]  Alan McClelland,et al.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.

[97]  J. Nicholson,et al.  Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics , 2002, Nature Medicine.

[98]  S. Walker,et al.  Biomarker discovery using molecular profiling approaches. , 2004, International review of neurobiology.

[99]  G. Blancho,et al.  Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[100]  J. Holt,et al.  Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[101]  E. Gutierrez,et al.  Detection of adenovirus DNA in peripheral blood mononuclear cells by polymerase chain reaction assay , 1997, Journal of medical virology.

[102]  M. Pfaffl,et al.  Modification of mRNA expression after treatment with anabolic agents and the usefulness for gene expression-biomarkers. , 2007, Analytica chimica acta.

[103]  Leigh Anderson,et al.  Candidate‐based proteomics in the search for biomarkers of cardiovascular disease , 2005, The Journal of physiology.

[104]  T. Henry,et al.  Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. , 2002, Journal of vascular surgery.

[105]  A. Wald,et al.  Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. , 1997, The Journal of infectious diseases.

[106]  O. Danos,et al.  Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice , 2006, Gene Therapy.

[107]  G. Cazorla,et al.  Perspectives in the Utilisation of Fourier-Transform Infrared Spectroscopy of Serum in Sports Medicine , 2000, Sports medicine.

[108]  S. Hoffman,et al.  Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. , 1999, Human gene therapy.

[109]  W. Dunn,et al.  Measuring the metabolome: current analytical technologies. , 2005, The Analyst.

[110]  Yi Zhang,et al.  Erythropoietin gene therapy leads to autoimmune anemia in macaques. , 2004, Blood.

[111]  Frederick P Roth,et al.  Metabolomic Identification of Novel Biomarkers of Myocardial Ischemia , 2005, Circulation.

[112]  D. Jolly,et al.  Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[113]  A. Mahfoudi,et al.  Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. , 2002, Human gene therapy.

[114]  D. Curiel,et al.  An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR-independent tropism and unique biodistribution in mice. , 2006, Virology.

[115]  D. Curiel,et al.  Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[116]  Jie Tian,et al.  Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[117]  Lukas N. Mueller,et al.  An integrated mass spectrometric and computational framework for the analysis of protein interaction networks , 2007, Nature Biotechnology.

[118]  C. Baum I could die for you: new prospects for suicide in gene therapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[119]  N. Yew Controlling the kinetics of transgene expression by plasmid design. , 2005, Advanced drug delivery reviews.

[120]  H. Stedman,et al.  Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. , 2005, Blood.

[121]  John Ellis,et al.  Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[123]  D. Baunsgaard,et al.  Combination of ‘omics’ data to investigate the mechanism(s) of hydrazine-induced hepatotoxicity in Rats and to identify potential biomarkers , 2004, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[124]  F. Khuri,et al.  Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  P. Sönksen,et al.  The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. , 2000, The Journal of clinical endocrinology and metabolism.

[126]  D. Pisetsky,et al.  Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice. , 1998, Journal of immunology.

[127]  J. S. St. George,et al.  Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery. , 2006, Human gene therapy.

[128]  R. Ventura,et al.  Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant erythropoietin misuse. , 2007, International journal of sports medicine.

[129]  K. Resing,et al.  Proteomics strategies for protein identification , 2005, FEBS letters.

[130]  R. Castelo,et al.  Monitoring Gene Therapy by External Imaging of mRNA: Pilot Study on Murine Erythropoietin , 2007, Therapeutic drug monitoring.

[131]  D. Pisetsky,et al.  Specificity and immunochemical properties of anti-DNA antibodies induced in normal mice by immunization with mammalian DNA with a CpG oligonucleotide as adjuvant. , 2003, Clinical immunology.

[132]  A. Judge,et al.  Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.

[133]  J. Yates Mass spectral analysis in proteomics. , 2004, Annual review of biophysics and biomolecular structure.

[134]  V. Hukkanen,et al.  Immune Response to Herpes Simplex Virus and ?134.5 Deleted HSV Vectors , 2005 .

[135]  Michael Buckley,et al.  Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. , 2006, The Journal of clinical endocrinology and metabolism.

[136]  D. Muruve,et al.  The innate immune response to adenovirus vectors. , 2004, Human gene therapy.

[137]  James M. Wilson,et al.  Humoral Immunity to Adeno-Associated Virus Type 2 Vectors following Administration to Murine and Nonhuman Primate Muscle , 2000, Journal of Virology.

[138]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[139]  N. Romero,et al.  Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. , 2004, Human gene therapy.

[140]  P. Fultz,et al.  Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[141]  N. Hackett,et al.  Variability of Human Systemic Humoral Immune Responses to Adenovirus Gene Transfer Vectors Administered to Different Organs , 1999, Journal of Virology.

[142]  Richard D. Smith,et al.  Proteomic analyses using an accurate mass and time tag strategy. , 2004, BioTechniques.

[143]  I. Alexander,et al.  Potential use of gene transfer in athletic performance enhancement. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[144]  Qiang Liu,et al.  Molecular basis of the inflammatory response to adenovirus vectors , 2003, Gene Therapy.

[145]  A. Annoni,et al.  Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. , 2004, Blood.

[146]  G. Goldspink Mechanical signals, IGF-I gene splicing, and muscle adaptation. , 2005, Physiology.

[147]  C. Dekker,et al.  A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. , 1995, Annals of internal medicine.